Aria CV Implants First Patient with Pulmonary Hypertension System
Aria CV Inc reports its first patient was implanted with the Gen 2 Aria CV Pulmonary Hypertension System.
Aria CV Inc reports its first patient was implanted with the Gen 2 Aria CV Pulmonary Hypertension System.
Inhaled nitric oxide has been utilized as a pulmonary vasodilator for over 20 years and research is ongoing to uncover the usefulness of iNO in several lung diseases and disorders.
A recent study highlights the importance of treating pulmonary hypertension in patients with obstructive sleep apnea.
New research from the American Heart Association revealed beta-blockers were not more likely to cause depression compared to other similar treatments, but the drugs may be linked to unusual dreams, insomnia and sleep disorders.
Read MoreJanssen Pharmaceutical Companies has submitted Uptravi (selexipag) as an injection for intravenous use for the treatment of pulmonary arterial hypertension.
Read MoreResults of a clinical trial show that patients with pulmonary hypertension (PH) have a lower capacity for exercise during hypoxia.
Read MoreHigh dose inhaled nitric oxide resulted in improvements in physical activity and other outcomes in patients at risk for pulmonary hypertension-associated fibrotic interstitial lung disease.
Read MoreIn certain patients, measurements of pulmonary artery (PA) distensibility are more effective at detecting pulmonary hypertension due to left heart disease than measurements of PA dilatation.
Read MoreAmong 111,356 veterans with pulmonary hypertension, only 1,737 (1.6%) patients received pulmonary rehabilitation.
Read MoreThe patient was treated under an emergency IND filed by a qualified Investigator and approved by the US FDA, according to the manufacturer Vero Biotech.
Read MoreThe implantable Aria CV Pulmonary Hypertension System has received a breakthrough device designation from the FDA, according to the manufacturer Aria CV.
Read MoreNew research found that the cardiac arrhythmia treatment Tikosyn (dofetilide) may be used for treatment of pulmonary arterial hypertension (PAH).
Read MoreFor patients with pulmonary arterial hypertension, updating the REVEAL risk calculator to include all-cause hospitalization was a better discriminator of risk than existing risk stratification tools.
Read MorePatients with pulmonary arterial hypertension (PAH) associated with systemic sclerosis (SSc) who...
Read MorePatients newly diagnosed with pulmonary arterial hypertension treated with macitentan and tadalafil combination therapy showed hemodynamic progress, as well as improvements in function and risk profile.
Read More